Scholarlink

<p>Oral contraceptive-associated hypertension is a long-recognized yet still under-recognized and potentially reversible contributor to elevated blood pressure in women, particularly adolescents and young adults. In Japan, prescribing of low-dose estrogen-progestin preparations has increased; however, available prescription data neither demonstrate an increase in oral contraceptive-associated hypertension nor establish a pill-specific rise in blood pressure among young women. Hormonal exposure may be overlooked because patients may not identify hormonal pills as blood pressure-relevant medicines and because contraceptive prescribing and hypertension assessment often occur in separate clinical settings. Oral contraceptive use may contribute to new-onset hypertension, worsening of established hypertension, apparent resistant hypertension, and misinterpretation of renin-angiotensin-aldosterone system testing. Blood pressure liability varies by formulation: ethinyl estradiol-containing combined hormonal contraceptives warrant the greatest concern, whereas drospirenone-containing or estradiol-based combined pills, progestin-only pills, and implants generally have lower or more neutral blood pressure signals. This review integrates targeted exposure recognition, formulation-specific assessment, home and ambulatory blood pressure monitoring, practical interpretation of a mildly elevated aldosterone-to-renin ratio, and coordinated management of women with new, worsening, or apparent resistant hypertension.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oral contraceptive-associated hypertension as an under-recognized contributor to secondary and apparent resistant hypertension: agent-specific blood pressure liability, RAAS testing pitfalls, and practical assessment

  • 期刊论文

  • 发表日期：

    2026年7月7日

查看全文
  • Yoshitaka Furuto,
  • Daiki Yoshino,
  • Akio Namikawa,
  • Dai Sato,
  • Yuko Shibuya

摘要

Oral contraceptive-associated hypertension is a long-recognized yet still under-recognized and potentially reversible contributor to elevated blood pressure in women, particularly adolescents and young adults. In Japan, prescribing of low-dose estrogen-progestin preparations has increased; however, available prescription data neither demonstrate an increase in oral contraceptive-associated hypertension nor establish a pill-specific rise in blood pressure among young women. Hormonal exposure may be overlooked because patients may not identify hormonal pills as blood pressure-relevant medicines and because contraceptive prescribing and hypertension assessment often occur in separate clinical settings. Oral contraceptive use may contribute to new-onset hypertension, worsening of established hypertension, apparent resistant hypertension, and misinterpretation of renin-angiotensin-aldosterone system testing. Blood pressure liability varies by formulation: ethinyl estradiol-containing combined hormonal contraceptives warrant the greatest concern, whereas drospirenone-containing or estradiol-based combined pills, progestin-only pills, and implants generally have lower or more neutral blood pressure signals. This review integrates targeted exposure recognition, formulation-specific assessment, home and ambulatory blood pressure monitoring, practical interpretation of a mildly elevated aldosterone-to-renin ratio, and coordinated management of women with new, worsening, or apparent resistant hypertension.